Posts for Ticker ‘AMLN’

The War On Diabetes Heats Up (NVO, AMLN, LLY, MNKD, PFE, VVUS, BMY, AZN, ARNA, GERN, STEM, OREX, GNBT, SPEX, ORMP, HDIX, PODD)

Biotech ImageDiabetes is becoming an epidemic in the U.S. and the Western World.  The ties to obesity are often direct, so the potential treatments are often directly tied as well.  We did a recent dig down for the next $170 billion opportunity for eight different major diseases and conditions, and now we have conducted a much deeper dig down specifically in the field of diabetes over at BioHealthInvestor.com.  We have recent and upcoming FDA action and data being presented from Novo Nordisk (NYSE: NVO), MannKind Corp. (NASDAQ: MNKD), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly (NYSE: LLY), Alkermes Inc. (NASDAQ: ALKS), Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN).  There is a mini-race going on between some of the later stage studies from obesity and diabetes candidates from Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), VIVUS, inc. (NASDAQ: VVUS), Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Amylin Pharmaceuticals Inc. (NASDAQ: AMLN).  Geron Corporation (NASDAQ: GERN) and StemCells Inc. (NASDAQ: STEM) were noted as two of the stem cell hopes, although stem cells may later rather than sooner.

Generex Biotechnology Corporation (NASDAQ: GNBT), Spherix Incorporated (NASDAQ: SPEX) and Oramed Pharmaceuticals Inc. (OTCBB: ORMP) were all noted in the much smaller or emerging plays.  Home Diagnostics, Inc. (NASDAQ:HDIX) and Insulet Corporation (NASDAQ: PODD) have both recently had key events as the interest in test equipment companies continues to remain high.

FULL STORY with much more detail at BioHealthInvestor.com.

Posted on: August 10, 2009 – 10:56 am in Biotech, Drug companies, FDA, Healthcare, Medical, , , , , , , , , , , , , , , , ,

Top Day Trader Alerts (CIT, ONXX, HGSI, WINN, OFG, AAPL, AMD, YHOO, SBUX, AMLN, GILD)

The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis at VSInvestor.com:

CIT Group Inc. shares (NYSE: CIT) are down on strong premarket volumes after Moody’s put some of its receivables-backed notes on review for a downgrade.

Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) is up strongly on high volume after it and Bayer announced that a Phase 2 trial in advanced metastatic breast cancer met the primary endpoint.

Human Genome Sciences Inc. (Nasdaq: HGSI) are rising on a government order for its Abthrax product.

Winn-Dixie Stores Inc. (Nasdaq: WINN) shares are up strongly in the early going on its EBITDA guidance.

Oriental Financial Group Inc. (NYSE: OFG) shares are up strongly on earnings and investment portfolio gains.

Apple Inc. (Nasdaq: AAPL) is up strongly on an earnings beat, and slightly better-than-expected iPhone sales.

Advanced Micro Devices Inc. (NYSE: AMD) shares are down sharply, and among the most actives, following a wider-than-expected loss, and disappointing gross margins.

Yahoo Inc. (Nasdaq: YHOO) shares are down in the early going on disappointing  guidance and less-than-expected search revenue.

Starbucks Corp. (Nasdaq: SBUX) shares are up strongly following better-than-expected fiscal Q3 results and fiscal 2009 guidance.

Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) shares are down on disappointing earnings.

Gilead Sciences Inc. (Nasdaq: GILD) shares are down, possibly after the company said U.S. wholesalers may decrease inventory levels of its HIV drugs.

-The 24/7 Wall St. Team

Posted on: July 22, 2009 – 7:53 am in Pre-Market Activity, Trading Alert, , , , , , , , , , ,

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details and analysis this morning at BioHealthInvestor.com:

Amgen Inc’s (Nasdaq: AMGN)’s osteoporosis drug did so well in a head-to-head Phase III trial vs. the current standard drug from Novartis Inc. (NYSE:  NVS) that the Amgen’s drug may become the new standard for patients with breast cancer.

Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), along with partners Eli Lilly & Co. (NYSE: LLY) and Alkermes Inc. (Nasdaq: ALKS), announced its new drug application for a once-weekly version of Byetta will be reviewed by the FDA, which may  help invigorate growth for the franchise.

Vical Inc. (Nasdaq: VICL) announced a positive four-month interim analysis for what is arguably its second-largest market opportunity, taking potentially another small step toward the goal of attracting a partner for its herpes vaccine program.

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) shares are down more than 7 percent on revenue and secondary offering fears. And Arena Pharmaceuticals Inc. (Nasdaq: ARNA) shares are falling after another dilutive offering.

Also, see our in-depth feature this week on five of the fastest-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 8, 2009 – 9:47 am in Biotech, Drug companies, FDA, Medical, , , , , , , , ,

Carl Icahn Holdings Show No Immunity To Market (IEP, BIIB, AMLN, MOT, YHOO, WMB, APC, TWX, TWC, AMD, TELK, QRCP, LEA, TIN, JCP)

Billionaire and activist investor Carl Icahn has made some  large changes to his portfolio holdings.  He and Icahn Capital, L.P. have not been immune to the market sell-off as you have seen in his Icahn Enterprises, L.P. (NYSE: IEP) share performance.  Here we have commented on some of his larger stakes and larger changes or exits in positions.

Stock Tickers noted as IEP, BIIB, AMLN, MOT, YHOO, WMB, APC, TWX, TWC, AMD, TELK, QRCP, LEA, TIN, and JCP.
Read More »

Posted on: February 14, 2009 – 2:16 pm in Activist Investor, Insider Activity, Value Investing, , , , , , , , , , , , , , , ,

Top Pre-Market Analyst Downgrades (AFFX, APD, ACAS, AMLN, AMAT, AINV, CTXS, DRYS, XOM, IRBT, LRCX, NFLX, NSR, NHY, NYX, BTU, UPS)

Burning_money_picThese are some of the top pre-market analyst downgrades and cautious calls we are seeing this Thursday morning:

  • Affymetrix (AFFX) Cut to Underweight at JPMorgan.
  • Air Products (APD) Cut to Neutral at JPMorgan.
  • American Capital (ACAS) Cut to Underperform at KBW.
  • Amylin Pharma (AMLN) Cut to Sell at Canaccord.
  • Applied Materials (AMAT) Started as Sell with $8 target at Auriga.
  • Apollo Investment (AINV) Cut to Market Perform at KBW.
  • Citrix Systems (CTXS) Cut to Neutral at Credit Suisse.
  • DryShips (DRYS) Cut to Underperform at Oppenheimer.
  • Exxon Mobil (XOM) Cut to Neutral at Goldman Sachs.
  • iRobot (IRBT) Cut to Neutral at JPMorgan.
  • Lam Research (LRCX) Cut to Underperform at Credit Suisse.
  • Netflix (NFLX) Started as Sell at Maxim Group.
  • Neustar (NSR) Cut to Neutral at JPMorgan.
  • Norsk Hydro (NHY) Cut to Market Perform at Bernstein.
  • NYSE Euronext (NYX) Cut to Neutral at Piper Jaffray.
  • Peabody Energy (BTU) Cut to Market Perform at FBR.
  • United Parcel Service (UPS) Cut to Underweight at Morgan Stanley.

Jon C. Ogg
January 29, 2009

Posted on: January 29, 2009 – 7:57 am in Analyst Calls, , , , , , , , , , , , , , , , ,

Top Pre-Market Analyst Downgrades (AMLN, BIIB, CIEN, XOM, GFA, MXIM, BTU, SLT, SPWRA)

Burning_money_picThese are some of the top pre-market downgrades and cautious calls we have seen from Wall Street analysts this Wednesday morning:

  • Amylin Pharmaceuticals (AMLN) Cut to Sell at Canaccord Adams.
  • Biogen Idec (BIIB) Started as Sell at Brean Murray.
  • Ciena (CIEN) Cut to Underperform at Credit Suisse.
  • Exxon Mobil (XOM) Cut to Neutral at UBS.
  • Gafisa (GFA) Cut to Neutral at UBS.
  • Maxim Integrated (MXIM) Cut to Equal Weight at Barclays.
  • Peabody Energy (BTU) Cut to Market Perform at FBR.
  • Sterlite Industries (SLT) Cut to Sell at Citigroup.
  • Sunpower (SPWRA) Cut to Accumulate at ThinkEquity.

Jon C. Ogg
January 28, 2009

Posted on: January 28, 2009 – 8:40 am in Analyst Calls, , , , , , , , ,

Diabetes Trifecta (AMLN, LLY, ALKS)

Amylin Pharmaceuticals, Inc., (NASDAQ: AMLN) has been a battered biotech lately.  But shares have just now gotten back above the single-digit threshold and are up more than 80% from recent lows.  This morning Amylin and partner Eli Lilly & Co. (NYSE: LLY) announced that the US FDA feedback on the DURATION-1 study is appropriate to use as the basis for demonstrating comparability between intermediate-scale clinical trial material made in Alkermes’ (NASDAQ: ALKS) manufacturing facility, and commercial-scale drug product made at Amylin’s manufacturing facility. 

Read More »

Posted on: December 11, 2008 – 10:10 am in Biotech, Drug companies, , ,

Top Pre-Market Analyst Downgrades (AAV, AMLN, CEPH, TV, VE)

Below are some of the top early bird analyst downgrades we have seen early this morning with more than two hours to the open:

  • Advantage Energy (AAV) Cut to Sector Perform at CIBC.
  • Amylin Pharmaceuticals (AMLN) Raised to Hold at Canaccord.
  • Cephalon (CEPH) Started as Overweight at JPMorgan.
  • Grupo Televisa (TV) Cut to Neutral at JPMorgan.
  • Veolia (VE) Cut to Hold at Citigroup.

Jon C. Ogg
October 7, 2008

Posted on: October 7, 2008 – 6:38 am in Analyst Calls, , , , ,

The 52-Week Low Club 8/27/2008 (F)(NEXM)(CEGE)(AMLN)

Sad_clownFord (F) Oil moves up. Drops to $4.25 from a 52-week high of $9.24.

Nexmed (NEXM) Drug trial problems. Falls to $.23 from a 52-week high of $.1.87.

Cell Genesys (CEGE) Drug trial problems. Plunges to $.69 from 52-week high of $4.67.

Amylin (AMLN) Deaths due to one of the company’s drugs. Dips to $19.92 from 52-week high of $51.10.

Douglas A. McIntyre

Posted on: August 27, 2008 – 2:54 pm in HI/LOW, , , ,

Top Pre-Market Analyst Upgrades & Downgrades (EXPO, EHTH, INCY, RIGL, WBD, AMR, AMLN, BKUNA, NGG)

It is getting pretty thin in analyst coverage as we get closer to Labor Day, but these are the upgrades and downgrades we are seeing this Wednesday morning:

  • Exponent (EXPO) Started as Buy at SunTrust.
  • eHealth (EHTH) Started as Buy at Merriman Curhan Ford.
  • Incyte (INCY) Started as Buy at Citigroup.
  • Rigel (RIGL) Started as Buy at Citigroup.
  • Wimm-Bill-Dann Foods (WBD) Raised to Buy at UBS.
  • AMR (AMR) Cut to Sell at Citigroup.
  • Amylin Pharma (AMLN) Cut to Neutral at Baird.
  • BankUnited (BKUNA) Cut To Sell at Stifel Nicolaus.
  • National Grid (NGG) Cut to Equal Weight at Lehman.

Jon C. Ogg
August 27, 2008

Posted on: August 27, 2008 – 7:37 am in Analyst Calls, , , , , , , , ,

Eli Lilly’s (LLY) Gift To The Funeral Industry

LlyThe National Funeral Directors Association must be sending “thank you” cards to Eli Lilly (LLY) and it partner Amylin (AMLN). Together, the companies developed and market diabetes drug Byetta. The firms had told the FDA that two people had died from the drug. That was bad enough. But, recently it added four more people to the list.

Read More »

Posted on: August 27, 2008 – 4:22 am in Pharmaceuticals, ,

24/7 Wall St. Most Overpaid CEO Of The Day: Amylin (AMLN) CEO Daniel M. Bradbury

95129cAmylin (AMLN) CEO Dan Bradbury earned a base salary of almost $560,000 last year according to the company proxy. He will probably do as well in 2008.

During the last twelve months, shares in the company are off 40%.

Yesterday, Federal regulators said they are working on a stronger label for a widely used diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. as deaths continue to be reported despite earlier government warnings.

The stock is likely to stay down for a long time

Douglas A. McIntyre

Posted on: August 19, 2008 – 7:04 am in Management Change,

Eil Lilly (LLY) Death Drug Needs More Regulation

LlyIf there wasn’t enough already wrong with the FDA drug approval process, diabetes drug Byetta, created for patients by Elli Lilly (LLY) and Amylin Pharmaceuticals (AMLN) is killing more people. The news follows an earlier report of problems which was put out by the agency in October.

Read More »

Posted on: August 18, 2008 – 2:29 pm in Pharmaceuticals, ,

Top 10 Pre-Market Analyst Calls (ALSK, AMLN, CX, FTO, NVDA, OVTI, BTU, QSFT, RBS, WBMD)

These are ten of the analyst calls we are focusing on this Wednesday morning:

  • Alaska Communications (NASDAQ: ALSK) Raised to Buy at Banc Of America Securities.
  • Amylin Pharmaceuticals (NASDAQ: AMLN) Raised to Equalweight at Lehman Brothers.
  • Cemex S.A.B. de C.V. (NYSE: CX) Cut to Underweight from Equal Weight at Morgan Stanley.
  • Frontier Oil (NYSE: FTO) Raised to Peer Perform at Bear Stearns.
  • Nvidia (NASDAQ: NVDA) Raised to Market-Outperform at JMP Securities.
  • OmniVision Tech (NASDAQ: OVTI) downgraded to Perform at Oppenheimer.
  • Peabody Energy (NYSE: BTU) Raised to Buy from Neutral at UBS.
  • Quest Software (NASDAQ: QSFT) Raised to Buy from Neutral at Goldman Sachs.
  • Royal Bank Of Scotland (NYSE: RBS) Raised to Neutral at Credit Suisse.
  • WebMD (NASDAQ: WBMD) Raised to Buy from Hold at Citigroup.

Jon C. Ogg
May 28, 2008

Posted on: May 28, 2008 – 6:04 am in Analyst Calls, , , , , , , , , ,

Can Carl Icahn Fix Broken Biotechs? (ANX, BIIB, ENZN, IMCL, TELK, FOLD, AMLN, REGN)

Carl Icahn is a billionaire financier, activist, and investor.  Most think of Icahn as an activist investor that wants to get inside and drive value without having to acquire the whole company to resell it later.  This strategy works and works well, so long as the right strategies and efforts are applied properly to each stock.  The underlying sector a company is in is critical too, and for some reason Carl Icahn has been trying to do this in biotech stocks.  We took the biotech filings from both Mr. Icahn’s own holdings and from Icahn Capital LP to see what Mr. Icahn thinks he has up his sleeves.

CARL ICAHN direct holdings, via several investment vehicles:

Adventrx Pharmaceuticals Inc. (AMEX: ANX) down 80% from highs

  • $467,000.00 for 864,865 shares

Biogen-Idec (NASDAQ: BIIB) down about 25% from highs 

  • $153.4M for 2,487,181 shares

Enzon Pharmaceuticals (NASDAQ: ENZN) down only 16% from highs

  • $5.6M for 614,420 shares

ImClone Systems (NASDAQ: IMCL) down 18% from highs

  • $494.9M for 11,669,544 shares

Telik Inc. (NASDAQ: TELK) down over 50% from highs

  • $2.536M for 1,039,165 shares

ICAHN CAPITAL LP direct holdings:

Adventrx Pharmaceuticals Inc. (AMEX: ANX) down 80% from highs

  • $1.8M for 3,459,459 shares

Amicus Therapeutics, Inc. (NASDAQ: FOLD) down 45% from highs

  • $2.16M for 201,940 shares

Amylin Pharmaceuticals Inc. (AMLN) down 40% from highs

  • $185.1M for 6,339,653 shares

APPLERA (NYSE: ABI) down 10% from highs

  • $21.3M for 649,026 shares

Biogen-Idec (NASDAQ: BIIB) down about 25% from highs 

  • $613.7M for 9,948,723 shares

Enzon Pharmaceuticals (NASDAQ: ENZN) down only 16% from highs

  • $22.6M for 2,457,683 shares

Regenron Pharmaceuticals (NASDAQ: REGN) down about 28% from highs

  • $48.1M for 2,508,001 shares

Telik Inc. (NASDAQ: TELK) down over 50% from highs

  • $10.1M for 4,156,663 shares

*** percentage down from highs means the 52-week highs, so many are off much more than all-time or historical highs.

It may not be fair to refer to all of these as broken, because many aren’t.  What is interesting here is that if you follow biotech stocks and if you know these companies, most of these have fallen from their former glory.

Here is the problem with biotech stocks: They almost HAVE to be public to live up to expectations, so they very rarely go private because of the need for capital.  The mere nature of putting molecules and modified products into your body has risks, and many companies cannot control what happens or how people their meds after a while.  Biotech companies cannot control the FDA and they cannot control independent verification or investigative studies.  No company can control whether or not a competitor comes out with a greater product.  Biotechs are different in that investors would rather see a biotech spend cash to acquire another biotech rather than engage in a share buyback or pay out a dividend.  When was the last time you heard a broker or an investor discuss the high dividend check they expect from their biotech?  Me neither…

Mr. Icahn has a great track record of influencing companies.  He made a fortune off the move in Time Warner.  Motorola has so far been a flop and Yahoo! is just getting started.  But he didn’t become a billionaire by throwing darts nor by investing in mutual funds. 

But there is a real discourse here from biotechs to other sectors, and it would just seem much easier for Mr. Icahn to get better returns elsewhere.  It might be easier backing high-risk and high-reward biotech ventures from scratch instead of trying to fix existing biotechs with problems.

You can join our open email distribution list to hear about activist investing, special financings, M&A, IPO’s, secondary offerings, and other special situations.

Jon C. Ogg
May 16, 2008

Posted on: May 16, 2008 – 10:43 am in Biotech, , , , , , , ,

Biotech Business Daily (AMLN, CERS, LLY, DNA, GTOP, IMCL)

Amylin Pharmaceuticals (NASDAQ: AMLN) reported first quarter losses of $68.8 million, or $0.51 EPS, wider than the $49.4 million in the first quarter of 2007. Losses are credited to a drop in sales in diabetes treatment, Byetta, a drug they co-market with Eli Lilly (NYSE: LLY), and increased expenses. Analysts estimated losses of $0.47 EPS. Shares are down over 8% to $28.83 on a 52-week range of $23.75 to $53.25.

Cerus Corporation (NASDAQ: CERS) up on news that the company can expand label claims on platelets and plasma treated with the INTERCEPT Blood System. The System prevents transfusion-associated disease, TA-GVHD. The label expansion allows use of the System over gamma irradiation in European blood banks for TA-GVHD prevention, decreasing costs to blood banks and increasing safety. Shares of Cerus are up almost 5% to $6.75. The 52-week range is $4.18 to $10.29.

Eli Lilly (NYSE: LLY) doubled profits, tagging a first quarter profit of $1.1 billion on a 14% sales increase. However, although doubling, they failed to meet Street estimates. Sales of depression drug Cymbalta rose 37% while sales of Zyprexa were flat and Byetta rose less than expected. The company raised its full-year guidance. Shares are down $2.26 to $49.81 on a 52-week range of $46.60 to $61.00.

Genentech (NYSE: DNA) released updated data on Avastin for the treatment of lung cancer. Results showed increased progression-free survival but not overall lung cancer survival rates. The already approved treatment in conjunction with chemotherapy is fighting for market share in the highly competitive market for this treatment. Shares are down $0.72 to $72 on a 52-week range of $65.35 to $82.90.

Genitope Corp (NASDAQ: GTOP) plummeting as GE Capital Corp. demanded payment on $3.8 million in loans last Friday. The company’s list of troubles is endless—failing Phase III testing, laying off 165 of 200 employees, salary cuts…and the latest failure to repay debts. Shares are down 16% today to $0.15, a new low. The 52-week range is $0.16 to $4.93.

ImClone (NASDAQ: IMCL) up on news that lung cancer competitor Genentech released disappointing late stage data on Avastin. ImClone’s similar drug, Erbitux, is currently in clinical trials. Shares are up $1.68 to $47.83, near 52 week highs. The 52-week range is $30.34 to $47.94.

Rachel Lopez
April 21, 2008

Posted on: April 21, 2008 – 11:54 am in Biotech, , , , , ,

Biotech Busine$$ Daily (ACAD, AMLN, CVTX, HALO, KOSN, MCU, NVAX, POZN, REGN, SIRT)

If you thought biotech news was getting quiet going into earnings season, think again.

Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment  for Parkinson’s disease psychosis (PDP) at the 60th American Academy of Neurology Annual Meeting today. According the results from the study, pimavanserin is safe and effective at improving psychosis scores without hindering motor abilities. Shares are up $0.46 to $8.36 on a 52-week range of $7.63 to $17.33.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up almost 3% in mid-morning trading. They announced that the earnings call is schedule for March 21. Trading at $30.42 on a 52-week range of $23.75 to $53.25.

CV Therapeutics, Inc. (NASDAQ: CVTX) soaring today after they announced Tuesday that they will receive $185 milliion from TPG-Axon Capital for rights to the sales of Lexiscan, a drug for patients that are unable to exercise during heart tests and was granted FDA approval last Thursday. Shares are up over 15% to $8.63 on a 52-week range of $5.41 to $13.74.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced pre-clinical findings in combinations of bisphosphonates and rHuPH20 at the American Association for Cancer Reseacrch conference today. The study showed that a combination of these molecules could reduce local irritation from chemotherapy by allowing a subcutaneous route of administration. Shares are up over 10% to $5.99 on a 52-week range of $4.19 to $11.00.

Kosan Biosciences Inc. (NASDAQ: KOSN) is still steadily rising after Monday announcement that Phase II testing for Epothilone KOS-1584 initiated. The drug targets patients with non-small cell lung cancer. Shares are up over 11% to $2.00 today. Monday, shares opened at $1.50. The 52-week range is $1.28 to $6.53.

Medicure Inc. (AMEX: MCU) up by 40% with the announcement that Phase II results for MC-1 and lisinpril for patients with type-II diabetes and hypertension will be presented at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference today. The data from the study was previously released. Shares are up 40% to $0.09 on a 52-week range of $0.05 to $1.64.

Novavax, Inc. (NASDAQ: NVAX) reported positive results in preclinical studies of Trivalent, a seasonal influenza vaccine. Phase II testing is hoped to begin in the third-quarter this year. Shares are up over 5% to $2.51. The 52-week range is $2.24 to $4.38.

Pozen, Inc. (NASDAQ: POZN) skyrocketing today on news that migraine drug Treximet has received FDA approval. They partnered with GlaxoSmithKline (GSK) for development of the drug. It is a follow up for Glaxo’s similar drug, Imitrex, which is set to lose patent protection in 2009. Pozen up 34% to $14.19 on a 52-week range of $8.29 to $19.75. Glaxo is up marginally to $42.57.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) moving higher than the rest today on no new developments. Shares are up $1.37 to $19.60 on a 52-week range of $13.55 to $28.74.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) published a report by Scientific Advisory Board Co-Chairs that showed first in-vivo data demonstrating that SIRT1 enzymes suppress tumor development in colon cancer cells. Shares are up almost 5% to $12.56 on a 52-week range of $9.50 to $21.99.

Rachel Lopez
April 16, 2008

Posted on: April 16, 2008 – 11:18 am in Biotech, , , , , , , , , ,

Biotech Busine$$ Daily (AMLN, BIIB, CEPH, CYTK, ONXX, REGN, THRX, CBM)

Many biotech stocks are enjoying large gains Monday, although some are on no real breaking news. Here is a look at some notable gainers:

  • Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up $1.39 to $28.97, a 5% increase. The 52-week range is $23.75 to $53.25.
  • Biogen Idec Inc. (NASDAQ: BIIB) up nearly $3.00, a 5% increase to $61.94. Carl Icahn on CNBC said today he is going to stay after the company.  The 52-week range is $43.43 to $84.75.
  • Cephalon Inc.  (NASDAQ: CEPH) up a modest 1% to $65.35. Last Thursday, they received FDA approval for Treanda, a treatment for chronic lymphocytic leukemia. The 52-week high is $84.83.
  • Cytokinetics, Incorporated (NASDAQ: CYTK) up over 2% to $3.49. Today the company announced positive results from Phase IIa trials of cardiac myosin activator drug CK-1827452 for patients with stable heart failure.
  • Onyx Pharmaceuticals (NASDAQ: ONXX) up $1.94 to $29.36, over 7% up. The 52-week range is $23.73 to $61.18
  • Regeneron Pharmaceuticals (NASDAQ: REGN) up $2.21 to $19.86, a 12% increase on the day. The 52-week range is $13.55 to $28.74
  • Theravance Inc. (NASDAQ: THRX) up $1.13 to $10.53, a 12% jump. The 52-week range is $9.37 to $36.98.

One biotech stock that isn’t enjoying the upswing is Cambrex Corp. (NYSE: CBM). The company hit a new low, down over 13% to $6.95 on news that UCB Groups Parkinson’s treatment, Neupro, is being recalled. Neupro uses their ingredient and the recall should impact earnings. First Analyis Sec downgraded the stock today.

Rachel Lopez
March 24, 2008

Posted on: March 24, 2008 – 2:00 pm in Biotech, , , , , , , ,

The 52-Week Low Club (AMLN, ARRS, AU, ED, GCI, IACI, IUSA, PCG, SLRY)

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is becoming a regular in this club. Yet another low of $28.02 intraday from a high of $53.25. It actually closed at $28.62, so it closed above the prior $28.41 low.

Arris Group Inc. (NASDAQ: ARRS). After an 86% drop in profit, shares plunge, targets are cut, and analysts downgrade, Arris lost 30% today and closed down at $5.50 from a former low of $6.91. The 52 week high is $17.89.

AngloGold Ashanti Ltd. (NYSE:AU)  A gold stock on the 52-week lows? Power issues prevail over high commodity prices… ouch! Trading at $33.75. The 52 week range is $33.80 to $51.35.

Consolidated Edison Inc. (NYSE:ED). $10 million lawsuit in the working from a mid-summer accident. Shares  down to $42.40, but $41.96 was the intraday low. The 52 week range is $42.35 to $52.90.

Gannett Co., Inc. (NYSE: GCI). It’s amazing when even a Warren Buffet stake won’t help a newspaper. Shares down to $31.90, prior 52-week range $31.97 to $63.50.

IAC/InteractiveCorp. (NASDAQ: IACI) has been under review for our special situations letter, although it has not yet been added with any formal recommendations. Shares actually closed up marginally at $21.88 after falling down to a low of $21.56; with a 52 week range of $21.80 to $52.90.

infoUSA Inc. (NASDAQ: IUSA) With such a lame Super Bowl commercial, what else could one ask for? Trading in at $7.82, but it traded as low as $7.50 today; preior range was $7.76 to $11.30.  We recently panned this one for our "10 Stocks Under $10" letter ahead of the big game.

PG & E Corp. (NYSE: PCG). As a reward for awards for environmental stewardship, this utility is given a new low. Trading at $39.85 it closed up marginally at the end of the day, but it saw $39.19 earlier today; 52-week trading range is $39.45 to $52.17.

Salary.com, Inc. (NASDAQ: SLRY).  We featured Salary.com on our "10 Stocks Under $10" letter as one of the worst ideas for an IPO of internet stocks and having potentially a fair value of $5 to $6 per share. Today, it reached a new low of $8.00 after a late morning nose-dive before coming back to close "only" down 2.8% at $8.32. The prior 52-week range was $8.31 to $16.32.

Douglas A. Mcintyre
February 15, 2008

Posted on: February 15, 2008 – 6:28 pm in HI/LOW, , , , , , , , ,

52-Week Low Club (AMLN, CYMI, NTCH, KEYN, MMA, NATI, STE, WTW)

There was a much larger list of companies which hit 52-week lows, but these were some of the larger percentage changes that we looked at:

  • Amylin Pharmaceuticals Inc. (AMLN) closed at $29.34 versus a prior 52-week low of $29.73 (high $53.25). Poor future outlook and inflated costs…. stock starting to look like the "Amylin-ville Horror."
  • Cymer Inc. (CYMI) down 20% to $27.00, prior 52-week range was $31.25 to $45.16. Cymer was downgraded after missing earnings yesterday.
  • Hutchinson Technology Inc. (NASDAQ: HTCH) fell 33% to $16.18; prior 52-week range was $17.69 to $27.85. Low sales projections and downgrades from Caris and Brean Murray.
  • Keynote Systems Inc. (KEYN) tanked 28% to $9.20 versus prior 52-week trading range of $10.35 to $17.35. A Bad note of losses and downgrades.
  • Municipal Mortgage & Equity LLC (NYSE: MMA) down 22% to $7.13, versus prior 52-week range of $9.05 to $32.20.  Woes continue, stock heading to pink sheets/OTC.
  • National Instruments Corp. (NASDAQ: NATI) fell almost 10% to $26.23, but intraday lows were $24.88; 52-week trading range $25.80 to $36.06.  Citi downgraded after Q1 earnings outlook looked short.
  • Steris Corp. (NYSE: STE) fell 14% to $23.48; prior 52-week range $24.65 to $31.71. It is involved in the development, manufacture, and marketing of infection prevention, contamination control, microbial reduction, and surgical and critical care support products and services.  For a nearly-recession proof business, you wonder why its outlook wasn’t in-line.
  • Weight Watchers (NYSE: WTW) fell 2.2% today to $41.94, although its intraday low was $41.49; prior 52-week trading range was $41.52 to $58.24.  No real news today, maybe losing weight equals losing share prices?  We doubt it.  This may be economically sensitive even if this is one of the few ongoing methods of weight loss that will actually work.

Jon C. Ogg
January 30, 2008

Posted on: January 30, 2008 – 4:53 pm in HI/LOW, , , , , , , ,